On the 6th, NH Nonghyup Life Insurance announced it would launch the ‘New NH Cancer Insurance’, which supports a targeted anticancer drug licensed treatment fund.
This product supports up to 50 million won for a targeted anticancer drug licensed treatment fund that attacks growth and spread by simply selecting cancer cells. In addition, small-scale cancers such as thyroid cancer and prostate cancer, which are classified as small-scale cancers under the main contract, are covered by additional mandatory special agreements. When registering for the main contract and a small number of special drugs for cancer diagnosis 10 million won each, thyroid cancer 10 million won, prostate cancer 6 million won, and other skin cancers, intravenous colon cancer, cancer in situ, limit tumor 3 million won paid only once for the first time.
In addition, in the case of a general cancer diagnosis, the full amount of insurance premiums paid in the main contract is returned as well as diagnosis insurance. In the case of non-renewal of the main contract, even for the diagnosis of two main diseases (cerebral hemorrhage, acute myocardial infarction), a special contract that returns the total amount of insurance premium on the main contract during the payment period can be selected.
This product can be easily subscribed to even those with high blood pressure, diabetes, or those with a history of cancer treatment who are unable to register.
If you do not have the following three notification items: hospitalization within 3 months, surgery, additional examinations, hospitalization within 2 years, and cancer diagnosis within 5 years, you can join.
The registration age is from 15 to 75 years. The subscription limit can be up to 30 million won in 10 million won units under the main contract. The insurance premium is 10 million won for subscription amount, payment for the first year, 20 years due, 40 years, type 1 (renewal type), 6200 won for men and 6700 won for women under pure insurance for general subscriptions.[이승훈 기자][ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]